中国医药追讨9800万业绩补偿

Core Viewpoint - China National Pharmaceutical Group (China Pharmaceutical) has achieved a preliminary legal victory in a contract dispute regarding performance compensation with Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. (Tibet Tiansheng), with the court ruling in favor of China Pharmaceutical for approximately 98.07 million yuan in compensation and interest [3][5]. Summary by Sections Legal Proceedings - The dispute originated in October 2024 when China Pharmaceutical filed a lawsuit against Tibet Tiansheng and Xu Panfeng over performance compensation issues [3]. - The court ruled that Tibet Tiansheng must pay China Pharmaceutical approximately 98.07 million yuan in performance compensation and interest, with Xu Panfeng bearing joint liability for the debt [5]. Financial Implications - The total amount involved in the case is approximately 139 million yuan, which could significantly impact China Pharmaceutical's financial status [5]. - The performance compensation of nearly 98 million yuan represents about one-third of China Pharmaceutical's net profit for the first half of 2025, which was reported at 29.4 million yuan, a decline of 16.19% year-on-year [6]. Performance Commitments - According to the original equity transfer agreement, Tibet Tiansheng made specific profit commitments for Henan Tongyong from March 2016 to February 2019, which were not met, leading to the dispute [3][4]. - An audit revealed that Henan Tongyong only exceeded the profit target in 2017, with significant shortfalls in other periods, totaling a discrepancy of 97.31 million yuan [4]. Current Status and Future Outlook - As of now, the first-instance judgment has not taken effect, and there remains uncertainty regarding whether Tibet Tiansheng will appeal the decision [5][6]. - China Pharmaceutical has indicated that it will actively respond to any appeals and disclose relevant information in future announcements [3].